Hyperammonemia induces programmed liver cell death
Hyperammonemia is common in liver cirrhosis and causally associated with hepatic encephalopathy development. Little is known about its hepatotoxic effects, which we aimed to characterize in this study. In a mouse model of chronic hyperammonemia without preexisting liver disease, we observed development of liver fibrogenesis and necroptotic cell death. Hyperammonemia also induced dysregulation of its main metabolic pathway, the urea cycle, as reflected by down-regulation of urea cycle enzyme protein expression and accumulation of its metabolites. Inhibition of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and its upstream inducer Toll-like receptor 4 (TLR4) protected against liver injury and further hyperammonemia. In clinically relevant rodent models of hyperammonemia (genetic ornithine transcarbamylase deficiency and bile duct ligation-induced cirrhosis), TLR4 inhibition reduced circulating ammonia. In conclusion, hyperammonemia induces liver fibrogenesis and RIPK1-mediated cell death, which is associated with urea cycle dysfunction. Inhibition of RIPK1 and TLR4 protects against hyperammonemia-induced liver injury and are potential therapeutic targets for hyperammonemia and chronic liver disease progression.
Authors
- Richard Moreau (ORCID: https://orcid.org/0000-0003-0862-403X)
- Joan Clària (ORCID: https://orcid.org/0000-0003-4333-7749)
- Christian Trautwein (ORCID: https://orcid.org/0000-0003-2762-8247)
- Ludovic Brunet
- Annarein Kerbert (ORCID: https://orcid.org/0000-0001-9845-2176)
- Andrew Hall (ORCID: https://orcid.org/0000-0001-5733-9484)
- Florence Castelli (ORCID: https://orcid.org/0000-0002-6886-8549)
- François Fenaille (ORCID: https://orcid.org/0000-0001-6787-4149)
- Mohsin Hassan (ORCID: https://orcid.org/0000-0002-3796-8846)
- Fausto Andreola (ORCID: https://orcid.org/0000-0003-4926-0121)
- Steven W.M. Olde Damink (ORCID: https://orcid.org/0000-0002-5202-9345)
- Varun U. Khetan (ORCID: https://orcid.org/0000-0003-2825-2157)
- Ines Volkert (ORCID: https://orcid.org/0009-0005-6094-8375)
- Rajiv Jalan (ORCID: https://orcid.org/0000-0002-7747-4015)
- Minneke J. Coenraad (ORCID: https://orcid.org/0000-0002-3434-4421)
- Gautam Mehta (ORCID: https://orcid.org/0000-0002-5696-359X)
- Ferrán Aguilar (ORCID: https://orcid.org/0000-0002-4367-8095)
- Vicente Arroyo (ORCID: https://orcid.org/0000-0002-2728-1848)
- Abeba Habtesion
- Pavitra Kumar (ORCID: https://orcid.org/0000-0002-8233-2273)
- Tobias Otto (ORCID: https://orcid.org/0000-0001-5594-3055)
- Tingting Qi (ORCID: https://orcid.org/0000-0001-8400-9456)
- Cornelius Engelmann
- Céline Chollet (ORCID: https://orcid.org/0009-0005-0428-7031)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Inserm (FR)
- TU Dortmund University (DE)
- Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR)
- Université Paris-Saclay (FR)
- Hôpital Beaujon (FR)
- Leiden University Medical Center (NL)
- The Royal Free Hospital (GB)
- Foundation for Liver Research (GB)
- Maastricht University (NL)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- European Foundation for the Study of Chronic Liver Failure (ES)
- Nanfang Hospital (CN)
- Hospital Clínic de Barcelona (ES)
- Feuerwehr Dortmund (DE)
- CEA Paris-Saclay (FR)
- Centre de Recherche sur l'Inflammation (FR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- University College London (GB)
- Southern Medical University (CN)
- Universitat de Barcelona (ES)
- Charité - Universitätsmedizin Berlin (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Science Advances
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1126/sciadv.ado1648
- Citations
- 11
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 14.50